Combination of statin/vitamin ID and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.

被引：0
|
作者：
de Velasco, Guillermo
Lora, David
Carretero-Gonzalez, Alberto
Martin Soberon, Maria Cruz
Sepulveda Sanchez, Juan Manuel Manuel
Lorente, David
Castellano, Daniel E.
机构：
[1] Univ Hosp 12 Octubre, Dept Med Oncol, I 12, Madrid, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Hosp Prov Castellon, Dept Med Oncol, Castellon De La Plana, Spain
[6] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6617
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
    A. Carretero-González
    D. Lora
    R. Manneh
    D. Lorente
    D. Castellano
    G. de Velasco
    Clinical and Translational Oncology, 2020, 22 : 2126 - 2129
  • [2] Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
    Carretero-Gonzalez, A.
    Lora, D.
    Manneh, R.
    Lorente, D.
    Castellano, D.
    de Velasco, G.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (11): : 2126 - 2129
  • [3] Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
    Pond, Gregory Russell
    Sonpavde, Guru
    Fizazi, Karim
    De Bono, Johann S.
    Basch, Ethan M.
    Scher, Howard I.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA
    Delanoy, N.
    Robbrecht, D.
    Fizazi, K.
    Mercier, F.
    Sartor, O.
    De Wit, R.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA.
    Delanoy, Nicolas
    De Bono, Johann S.
    Mercier, Florence
    Geffriaud-Ricouard, Christine
    Eisenberger, Mario A.
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trials
    Leibowitz-Amit, Raya
    Pintille, Melanie
    Laird, A. Douglas
    Aftab, Dana T.
    Berger, Raanan
    Chi, Kim N.
    Joshua, Anthony M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [7] Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials
    Pan, Jian
    Wang, Jun
    Wei, Yu
    Zhang, Tingwei
    Zhang, Sheng
    Ye, Dingwei
    Zhu, Yao
    CANCER MEDICINE, 2021, 10 (19): : 6697 - 6704
  • [8] Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
    Delanoy, Nicolas
    Robbrecht, Debbie
    Eisenberger, Mario
    Sartor, Oliver
    de Wit, Ronald
    Mercier, Florence
    Geffriaud-Ricouard, Christine
    de Bono, Johann
    Oudard, Stephane
    CANCERS, 2021, 13 (06) : 1 - 13
  • [9] Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
    de Velasco, Guillermo
    Lora, David
    Lorente, David
    Choueiri, Toni K.
    Sweeney, Christopher
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
    Hahn, A. W.
    Tidwell, R. S.
    Surasi, D. S.
    Msaouel, P.
    Efstathiou, E.
    Zurita-Saavedra, A. J.
    Tu, S-M.
    McQuade, J. L.
    Fogelman, D.
    Starbuck, M. W.
    Subudhi, S. K.
    Corn, P.
    Pilie, P. G.
    Aparicio, A.
    Logothetis, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S538 - S538
12345